Last reviewed · How we verify
Alindapril (DELAPRIL)
Alindapril (generic name: DELAPRIL) is a delapril drug. It is currently in Phase 3 development for Hypertensive disorder.
Delapril works by blocking the action of angiotensin-converting enzyme, a protein that constricts blood vessels.
Alindapril, also known as Delapril, is a small molecule drug that targets the angiotensin-converting enzyme (ACE). It belongs to the delapril class and is used to treat hypertensive disorders. The commercial status of Delapril is unclear, but it is likely to be patented or off-patent. Delapril has a bioavailability of 55%, but its half-life and generic manufacturers are unknown. As a result, its FDA approval status and off-patent status are also unclear.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DELAPRIL |
|---|---|
| Drug class | delapril |
| Target | Angiotensin-converting enzyme |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Think of your blood vessels like roads in a city. When the angiotensin-converting enzyme is active, it's like a traffic cop directing more traffic onto the roads, making them narrower and harder to pass through. Delapril blocks this traffic cop, allowing the roads to stay open and blood to flow more easily.
Approved indications
- Hypertensive disorder
Common side effects
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) (PHASE3)
- A Study to Evaluate the Effects of Manidipine Versus Amlodipine and the Combination of Manidipine Plus Delapril Versus Amlodipine Plus Delapril on Intraglomerular Pressure in Hypertensive Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alindapril CI brief — competitive landscape report
- Alindapril updates RSS · CI watch RSS
Frequently asked questions about Alindapril
What is Alindapril?
How does Alindapril work?
What is Alindapril used for?
What is the generic name of Alindapril?
What drug class is Alindapril in?
What development phase is Alindapril in?
What does Alindapril target?
Related
- Drug class: All delapril drugs
- Target: All drugs targeting Angiotensin-converting enzyme
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertensive disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing